Sentence examples for prior progression from inspiring English sources

CI for AP and BC were calculated with "death without prior progression" as competing event.

Recently, a phase II study of sunitinib also achieved prolonged tumor stabilization, of >6 months, in 62% of patients with documented prior progression [ 16].

The FDA has approved lapatinib in combination with capecitabine for treatment of HER2 positive breast cancer with prior progression on trastuzumab, an anthracycline, and a taxane.

Competing risks techniques allow for a more specific analysis in that they consider time until occurrence of the combined endpoint and endpoint type, e.g., progression in contrast to death without prior progression.

We focused on treatments delivered after prior progression with the same or similar agents; more than one in eight patients received at least one regimen that is not considered standard of care.

Kaern et al. [ 46] studied taxane rechallenge after platinum/paclitaxel therapy and found that the likelihood to respond to second-line paclitaxel is largely unaffected by the prior progression free interval.

Second, we further examined annualized costs among only those patients who progressed, comparing costs prior to progression with costs incurred following progression.

In the combination group, 38% (76 of 198) of patients experienced a Grade 3/4 AE prior to progression or censoring for progression, with an average start time of 67 days after randomisation.

A total of 54% (67 out of 124) of panitumumab+BSC patients and 27%3232 out of 119) of BSC alone patients experienced a ⩾grade 3 AE prior to progression or censoring for progression.

In comparing change in costs over time incurred by patients who did and did not progress (Table 3), the annualized follow-up costs among those who progressed comingles costs that occurred prior to progression with those that occurred following progression.

56 This Q-TWiST analysis evaluated the trade-off between toxicity and PFS by taking into account the time spent by each patient with or without grade 3 or 4 toxicity prior to progression and the time from progression to death or end of follow-up.